Which contrast agent is preferred in patients with reduced renal function due to lower nephrotoxicity?

Which contrast agent is preferred in patients with reduced renal function due to lower nephrotoxicity?

• A. Omnipaque
• B. Visipaque
• C. Gastrografin
• D. Gastromiro

Answer: (B)

In patients with reduced renal function, the risk of contrast-induced nephropathy is a major concern, so using a contrast agent with osmolality closest to blood helps protect the kidneys. Visipaque is iodixanol, an iso-osmolar contrast agent, meaning its osmolality is about the same as plasma. That lower osmotic load reduces renal vasoconstriction and tubular stress, making it the preferred choice when kidney function is a concern. Omnipaque (iohexol) is a low-osmolar agent, which is safer than older high-osmolar contrasts but does not match the iso-osmolar profile of Visipaque. Gastrografin is hyperosmolar and carries a higher risk of nephrotoxicity, so it’s less suitable in CKD. Gastromiro isn’t a standard clinically used contrast in this context. So, the iso-osmolar option Visipaque best minimizes nephrotoxicity in patients with reduced renal function.

In patients with reduced renal function, the risk of contrast-induced nephropathy is a major concern, so using a contrast agent with osmolality closest to blood helps protect the kidneys. Visipaque is iodixanol, an iso-osmolar contrast agent, meaning its osmolality is about the same as plasma. That lower osmotic load reduces renal vasoconstriction and tubular stress, making it the preferred choice when kidney function is a concern.

Omnipaque (iohexol) is a low-osmolar agent, which is safer than older high-osmolar contrasts but does not match the iso-osmolar profile of Visipaque. Gastrografin is hyperosmolar and carries a higher risk of nephrotoxicity, so it’s less suitable in CKD. Gastromiro isn’t a standard clinically used contrast in this context.

So, the iso-osmolar option Visipaque best minimizes nephrotoxicity in patients with reduced renal function.